Cohort event monitoring of patients treated for uncomplicated malaria with artemisinin-based combination therapies in selected hospitals and community pharmacies in Nigeria.

Clicks: 342
ID: 15813
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #6 of 62 articles by views in the nigerian postgraduate medical journal

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The study was designed with the broad objective of determining the safety profile of artemisinin-based combination therapies amongst Nigerian population.This was a cohort event monitoring (CEM) programme involving monitoring adverse events (AEs) in malaria patients treated with either artemether-lumefantrine (AL) or artesunate-amodiaquine (AA) in healthcare facilities in Nigeria. The study involved continuous enrolment of patients with malaria and treated with either AL or AA at the various sites until a total cohort of 600 patients were enrolled at each site. Patients were monitored from the onset of therapy, and on days 3 and 7 from the first day of treatment to identify AEs that may occur.A total of 6102 AEs were recorded in 10,259 patients monitored during the programme. Of 4896 patients who received AA, 4233 (86.5%) patients reported at least one AE while 1869 (34.8%) AEs out of 5363 patients who received AL were reported (P = 0.010). The predominant incidence of each specific AE reported in each group among the patients who received AA and AL includes body weakness 30.8%/7.5%, dizziness 10.3%/3.9%, restlessness 5.02/1.12%, vomiting 3.5/1.03% and drowsiness 3.1/1.5% for AA and AL, respectively. There were more AEs among patients with co-morbid conditions and patients in the younger age groups (9-<15 years), P = 0.000.Various types of AEs were seen and documented during the CEM programme. The findings suggested that the AA/AL monitored during this programme was generally safe and remarkably well tolerated among the Nigerian populations.
Reference Key
bassicohortthe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bassi, P U;Osakwe, A I;Suku, C;Kalat, M;Elagbaje, C;Isah, A;Ayinbuomwan, S;Wammanda, R D;Bob-Okon, I I;Ambe, J;Mava, Y;Adesina, A O;Ugochukwu, C G;Nyong, E E;Ogunleye, O O;Onuoha, F;Jalo, I;Adegoke, V O;Balogun, S T;Ntadom, G;Ejiekpe, F N;Tahir, R;Dabit, K;Amodu, A A;Nwaosu, S;Habib, A T;
Journal the nigerian postgraduate medical journal
Year Year not found
DOI
10.4103/1117-1936.196246
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.